ClinicalTrials.gg
Not yet recruitingNCT07851714MET-MNDUpdated Oct 1, 2026

Metabolism and Nutrition in MND

An observational study in Amyotrophic Lateral Sclerosis (ALS) and Motor Neurone Disease (MND), sponsored by Guy's and St Thomas' NHS Foundation Trust. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Guy's and St Thomas' NHS Foundation Trust · Observational

How we know

Updated Oct 1, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
12
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies in Amyotrophic Lateral Sclerosis with a site in United Kingdom — 15 open to participants now, 22 under way, 6 of them phase 3. Amyotrophic Lateral Sclerosis · United Kingdom.

Planned enrollment
15th of 15
12 · median 73
Started
2026
with 6 others
Observational
15 of 70
8 open now
Primary completion
2029-12
later than 19 of 21 live
Registered
68th of 70
by date
Lead sponsor
2 of 70
Guy's and St Thomas' NHS Foundation Trust

Among the 70 studies in Amyotrophic Lateral Sclerosis with a site in United Kingdom, this one is the 15th largest by planned enrollment of the 15 observational ones that give a count, is one of 7 that started in 2026, is one of 15 observational ones, reaches primary completion later than 19 of the 21 other live ones, and was the 68th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

15 of the 70 studies in Amyotrophic Lateral Sclerosis with a site in United Kingdom are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Amyotrophic Lateral Sclerosis with a site in United Kingdom, or all of them as a file.
02

Study summary

Motor neurone disease (MND) is a progressive neurological condition that can affect movement, speech, swallowing and breathing. Weight loss and malnutrition are common in people with MND and may be caused by factors including swallowing difficulties, reduced food intake, fatigue, breathlessness, loss of muscle mass and changes in the amount of energy the body uses at rest.

Resting energy expenditure can be measured using indirect calorimetry. However, there is limited evidence about whether comprehensive metabolic, nutritional and body composition assessments can be completed acceptably and practically by people with MND during routine clinical appointments.

MET-MND is a single-centre observational feasibility study involving approximately 12-15 adults with MND referred to a specialist respiratory service. Participants will complete one study visit aligned with a routine clinic appointment, followed by a 7-day food diary at home.

The study will evaluate the acceptability, tolerability, practicality, completion and data completeness of metabolic, nutritional and body composition assessments. Findings will be used to refine study procedures and inform the design of future research investigating metabolism and nutrition in people with MND.

Read the detailed description

MET-MND is a single-centre observational feasibility study conducted within Lane Fox Respiratory Services at Guy's and St Thomas' NHS Foundation Trust. The study will assess the feasibility, acceptability, tolerability and data completeness of collecting metabolic, nutritional and body composition measurements in adults with motor neurone disease during the routine respiratory clinic pathway.

Approximately 12-15 participants will complete one study visit aligned with a routine clinic appointment. The study visit is expected to take approximately 1-1.5 hours. Participants will subsequently complete a 7-day food diary at home.

Metabolic rate will be measured using indirect calorimetry with the Q-NRG+ indirect calorimeter. The assessment will be performed while the participant is resting, using either a ventilated canopy hood or mask according to participant comfort and clinical suitability. The study will assess whether indirect calorimetry can be completed successfully and whether the hood or mask is more suitable for people with MND.

Nutritional assessment will include weight, height, body mass index, percentage weight loss and Subjective Global Assessment. Body composition will be assessed using bioelectrical impedance analysis and skinfold measurements. Participants will also complete the ALS Functional Rating Scale-Revised to record how MND affects day-to-day function.

Participants will be asked to record their food and drink intake for seven consecutive days using the Nutritics Libro app or a paper food diary. The diary will be analysed to estimate energy and protein intake. Assistance with completing the diary may be provided when required.

Participants will be asked a small number of questions about the acceptability of undergoing a Dual-Energy X-ray Absorptiometry scan in future research. No DEXA scan will be performed as part of this feasibility study.

Study feasibility will be evaluated using assessment completion, data completeness, time required, participant acceptability and tolerability, and practical or operational barriers encountered during delivery. Reasons for incomplete assessments, such as fatigue, breathlessness, positioning difficulties or equipment limitations, will be recorded.

Measurements will follow written study procedures. Operator-dependent measurements, including skinfold measurements, will be performed in duplicate or triplicate as specified in the protocol. Analyses will be descriptive and will summarise feasibility measures using frequencies, percentages, means with standard deviations, or medians with interquartile ranges, as appropriate. Reasons for non-completion and barriers to delivery will be summarised narratively.

Findings will be used to refine and optimise the assessment procedures, evaluate participant burden and inform the design of future observational research investigating metabolism and nutrition in MND.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis (ALS)
  • Motor Neurone Disease (MND)

Keywords

  • Nutrition
  • Weight loss
  • metabolic rate
  • indirect calorimetry
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Hospital outpatient department

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult MND patients aged 18 years or over at the time of giving consent.
  • Newly referred to the specialist respiratory service for assessment

Exclusion criteria

Exclusion Criteria:

  • Lacking capacity to provide fully informed written consent, verbal consent (for those who cannot provide written consent), or consent via the use of a communication aid
  • Inability to understand the study's protocol (cognitive disorders)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
12 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Percentage of planned metabolic, nutritional and body composition assessments completed

    For each participant, completion status will be recorded for the following planned assessments: indirect calorimetry, Subjective Global Assessment, weight and height measurements, bioelectrical impedance analysis, skinfold measurements, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised, DEXA acceptability questions and the 7-day food diary. The number and percentage of participants completing each assessment will be reported separately. Reasons for non-completion will also be recorded.

    Time frame: From Day 1 through Day 8. Day 1: single study visit. Days 2-8: seven days following the visit for diary completion

  2. Percentage of Required Data Fields Completed for Each Planned Study Assessment

    Data completeness will be assessed separately for indirect calorimetry, Subjective Global Assessment, anthropometry, bioelectrical impedance analysis, skinfold measurements, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised, DEXA acceptability questions and the 7-day food diary. The percentage of completed data fields will be reported for each assessment. Reasons for missing data will be recorded.

    Time frame: From Day 1 through Day 8.

Secondary outcomes

  1. Participant acceptability and tolerability: number of participants unable to complete each assessment due to acceptability or tolerability of study assessments

    Participant acceptability and tolerability will be assessed for the metabolic, nutritional and body composition procedures. The number and percentage of participants who complete, stop, decline or require adaptation of each assessment will be summarised. Recorded reasons may include discomfort, fatigue, breathlessness, claustrophobia, positioning difficulty or other participant-reported or clinical factors.

    Time frame: From Day 1 through Day 8

  2. Time taken to complete each in clinic study assessment

    The time taken to complete each metabolic, nutritional and body composition assessment will be recorded in minutes: will include indirect calorimetry, Subjective Global Assessment, anthropometry, bioelectrical impedance analysis, skinfold measurements, the ALS Functional Rating Scale-Revised and the DEXA acceptability questions.

    Time frame: Day 1

  3. Practicality of integrating assessments into the routine respiratory clinic pathway: percentage completing all in-clinic assessments during one routine clinic visit

    The number and percentage of participants for whom all planned in-clinic assessments are completed within the single routine clinic visit will be reported. Operational factors affecting delivery, including room availability, equipment availability, workflow, participant positioning and need for breaks or adaptations, will be recorded and summarised descriptively.

    Time frame: Day 1

  4. Completion of Indirect Calorimetry using a canopy hood or mask

    The number and percentage of participants who complete indirect calorimetry will be reported by measurement method: ventilated canopy hood or mask. Any need to stop or adapt the procedure and the reasons for non-completion will be recorded.

    Time frame: Day 1

  5. Number of Days Completed in the 7-Day Food Diary

    The number of diary days completed by each participant using the Nutritics Libro app or paper diary will be recorded, with a possible range of 0-7 days. The number and percentage of participants completing all seven days will also be reported. The availability of information required to estimate energy and protein intake, support required and reasons for incomplete diary data will be summarised.

    Time frame: Day 2-8

  6. Participant Responses to the DEXA Acceptability Questions

    Responses to the study-specific DEXA acceptability questions will be summarised using the response options specified in the questionnaire. The questions assess whether participants might consider undergoing a DEXA scan in future research and identify practical concerns that could affect acceptability. No DEXA scan will be performed in this study.

    Time frame: Day 1

07

Study locations

1 site
08

References and documents

Publications

  • 1. British Thoracic Society Standards of Care Committee. (2002). 'Non-invasive ventilation in acute respiratory failure', Thorax, 57:192-211. doi: 10.1136/thorax.57.3.192. PMID: 11867822; PMCID: PMC1746282. 2. Cedarbaum, J.M., Stambler, N., Malta, E., et., (1999). The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). Journal of the Neurological Sciences, 169(1-2), pp.13-21. https://doi.org/10.1016/S0022-510X(99)00210-5 3. MNDA (2023) Motor Neurone Disease Association Key messages and core information. Available at https://www.mndassociation.org/sites/default/files/2023-05/MND%20Association%20key%20messages%20updated%20May%202023.pdf (Accessed: 6/8/2025). 4. National Institute of Neurological Disorders and Stroke (NINDS). [online, accessed 28 November 2025]. Last updated 26 March 2025. Available from: https://www.ninds.nih.gov/health-information/disorders/motor-neuron-diseases?search-term=MND 5. MND Association. [online, accessed 28 November 2025]. Available from: MND Association key messages infographic May 2023.pdf 6. Cederholm, T. et al. ESPEN guidelines on definitions and terminology of clinical nutrition Clinical Nutrition, Volume 36, Issue 1, 49 - 64. 6a. The British Association for Parenteral and Enteral Nutrition (BAPEN). [online, accessed 27 November 2025]. 7. Nutrition Support for Adults (2006). NICE guideline CG32. Last updated 4 August 2017. 8. Stratton RJ, Smith TS and Gabe SG. 2018. Managing malnutrition to improve lives and save money. [online, accessed 27 November 2025]. Available from: https://www.bapen.org.uk/pdfs/reports/mag/managing-malnutrition.pdf 9. Muscaritoli M, Kushta I, Molfino A, et al. Nutritional and metabolic support in patients with amyotrophic lateral sclerosis. Nutrition. 2012; 28:959-66. 10. Zarco-Martín MT, Freire C, Andreo-López MC, et al. Malnutrition in Amyotrophic Lateral Sclerosis: Insights from Morphofunctional Assessment and Global L

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Dec 2029, 38 months later.

Of 129 non-industry observational studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 125. This study's planned 38 months is below that.

Counting every sponsor, half of 138 studies reached it within 64 months; a quarter within 29 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2026
First posted
Oct 1, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07851714
Responsible party
Sponsor
First posted
Oct 1, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Oct 1, 2026

Study contacts

Angela Reddy
Contact
angelareddy@nhs.net
+442071888070
Gillian Radcliffe
study chair · Guy's and St Thomas' NHS Foundation Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion